FierceBiotech Radio show

FierceBiotech Radio

Summary: FierceBiotech brings you interviews and analysis from around the biotech, pharma and medical device industries.

Podcasts:

 GSK's CEO shakeup, Lilly's Alzheimer's uncertainty, and Valeant's latest disaster | File Type: audio/mpeg | Duration: 28:41

GSK's CEO shakeup, Lilly's Alzheimer's uncertainty, and Valeant's latest disaster

 The FDA's new boss, Sanofi's latest shortcut, and a little 'financial innovation' | File Type: audio/mpeg | Duration: 41:26

The FDA's new boss, Sanofi's latest shortcut, and a little 'financial innovation'

 Pharma's TV blitz, biotech's IPO trickle, and the M&A future of Intercept Pharmaceuticals | File Type: audio/mpeg | Duration: 39:23

Pharma's TV blitz, biotech's IPO trickle, and the M&A future of Intercept Pharmaceuticals

 Pharma's day on the Hill, biotech's paucity of M&A, and the gathering storm of biosimilars | File Type: audio/mpeg | Duration: 40:30

Pharma's day on the Hill, biotech's paucity of M&A, and the gathering storm of biosimilars

 Gilead's wide-open future, biotech's long winter, and Sanofi's ongoing makeover | File Type: audio/mpeg | Duration: 36:41

Gilead's wide-open future, biotech's long winter, and Sanofi's ongoing makeover

 Shire's byzantine Baxalta pursuit, biotech's pragmatic winter and Valeant's CEO shakeup | File Type: audio/mpeg | Duration: 22:37

Shire's byzantine Baxalta pursuit, biotech's pragmatic winter and Valeant's CEO shakeup

 The burning hole in Gilead's $25B pocket and AbbVie's future in hematology | File Type: audio/mpeg | Duration: 19:52

The burning hole in Gilead's $25B pocket and AbbVie's future in hematology

 Gilead's maxed-out revenue, BioMarin's FDA struggles, and GSK's rock and hard place | File Type: audio/mpeg | Duration: 24:31

Gilead's maxed-out revenue, BioMarin's FDA struggles, and GSK's rock and hard place

 The ins and outs of 'Pfizergan,' whatever it is Martin Shkreli's doing and the end of two takeover battles | File Type: audio/mpeg | Duration: 28:35

The ins and outs of 'Pfizergan,' whatever it is Martin Shkreli's doing and the end of two takeover battles

 Sanofi's middling future, Amgen's $10B shopping list, and a novel pharma lawsuit | File Type: audio/mpeg | Duration: 32:02

Sanofi's middling future, Amgen's $10B shopping list, and a novel pharma lawsuit

 Fraud's not that big of a deal: the Valeant story, according to Bill Ackman | File Type: audio/mpeg | Duration: 29:46

Fraud's not that big of a deal: the Valeant story, according to Bill Ackman

 Valeant's semantic innovation, Pfizer's future and the slow trickle of biotech IPOs | File Type: audio/mpeg | Duration: 25:08

Valeant's semantic innovation, Pfizer's future and the slow trickle of biotech IPOs

 Doomsdays for Valeant, Biogen and biotech VC | File Type: audio/mpeg | Duration: 21:50

Doomsdays for Valeant, Biogen and biotech VC

 Lilly's latest pipeline peril, Mylan's M&A broken record, and German Merck's big rebrand | File Type: audio/mpeg | Duration: 28:55

Lilly's latest pipeline peril, Mylan's M&A broken record, and German Merck's big rebrand

 Biotech's Wall Street malaise, Valeant's Washington woes, and immuno-oncology's primetime slot | File Type: audio/mpeg | Duration: 26:30

Biotech's Wall Street malaise, Valeant's Washington woes, and immuno-oncology's primetime slot

Comments

Login or signup comment.